| abstract |
The compounds of the formula (I) wherein, Z is -N or> CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or phenyl, each substituted or unsubstituted in a carbon ring member with one or two halves Ra; wherein each Ra half is independently selected from the group consisting of -C1-4alkyl, -C2-4alkenyl, -OH, -OC1-4alkyl, halo, -CF3, -OCF3, -SCF3, -SH, -SH, -S (O) 0-2C1-4alkyl, -OSO2C1-4alkyl, -CO2C1-4alkyl, -CO2H, -COC1-4alkyl, -N (Rb) Rc, -SO2NRbRc, -NRbSO2Rc, -C (= O) NRbRc, -NO2 and -CN, wherein Rb and Rc are each independently -H or -C1-4alkyl; and Ar2 is defined in the claims that are useful as FAAH inhibitors. Such compounds can be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by the activity of fatty acid amide hydrolase (FAAH). So, the compounds can be administered to treat e.g. anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). |